We are experiencing some temporary issues. The market data on this page is currently delayed. Please bear with us as we address this and restore your personalized lists.
S&P Futures
5,178.50 +11.00 (+0.21%) Dow Futures
38,309.00 +71.00 (+0.19%) Nasdaq Futures
18,222.75 +43.50 (+0.24%) Russell 2000 Futures
2,030.00 +10.20 (+0.50%) Crude Oil
85.41 -0.25 (-0.29%) Gold
2,371.30 -2.80 (-0.12%)
After hours:
Chart Events
Performance Outlook
| Previous Close | 244.00 |
| Open | 242.38 |
| Bid | 239.01 x 800 |
| Ask | 240.40 x 1000 |
| Day's Range | 239.00 - 243.18 |
| 52 Week Range | 182.09 - 259.00 |
| Volume | |
| Avg. Volume | 2,648,724 |
| Market Cap | 177.694B |
| Beta (5Y Monthly) | 0.86 |
| PE Ratio (TTM) | 42.54 |
| EPS (TTM) | 5.64 |
| Earnings Date | Apr 23, 2024 |
| Forward Dividend & Yield | 1.08 (0.45%) |
| Ex-Dividend Date | Mar 27, 2024 |
| 1y Target Est | 263.76 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for DHR
Related Research
- Danaher CorporationWeekly Stock ListWe see what we believe are some great opportunities right now in Healthcare -- and we like the sector overall. Argus Director of Research Jim Kelleher, CFA, recently completed his quarterly sector review and raised Healthcare sector to Over-Weight from Market-Weight. The healthcare environment is undergoing rapid transitions, and we now see an unfolding period of significant promise and opportunity. Our newly-favored stance is based on resumption of deferred medical procedures and significant new quality-of-life drugs and treatments. The category is broad and has underperformed the S&P 500 over the past year. The Healthcare sector ETF (XLV) is up 15% over the past year compared to a gain of 31% for the S&P 500. We see opportunity here to pick up some steady companies, with big brands and solid financials. These companies are science-focused and enhance lives. They are innovators. In our list this week, we look across several subsectors within the Healthcare sector and pull out some leaders we like. These stocks also are included in our Focus List and Model Portfolios, as noted below.RatingFair ValueEconomic Moat28 days agoArgus Research
ZacksReasons Why Danaher (DHR) Should be in Your Portfolio Now
Danaher (DHR) is set to benefit from strength across its businesses, acquired assets and shareholder-friendly policies.
ZacksHere's Why Danaher (DHR) Gained But Lagged the Market Today
In the closing of the recent trading day, Danaher (DHR) stood at $244.28, denoting a +0.98% change from the preceding trading day.
ZacksInvestors Heavily Search Danaher Corporation (DHR): Here is What You Need to Know
Danaher (DHR) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
ZacksDanaher (DHR) Suffers a Larger Drop Than the General Market: Key Insights
In the closing of the recent trading day, Danaher (DHR) stood at $245.94, denoting a -0.75% change from the preceding trading day.
ZacksDanaher (DHR) Rises Yet Lags Behind Market: Some Facts Worth Knowing
Danaher (DHR) reachead $248.77 at the closing of the latest trading day, reflecting a +0.12% change compared to its last close.
ZacksWall Street Analysts See Danaher (DHR) as a Buy: Should You Invest?
According to the average brokerage recommendation (ABR), one should invest in Danaher (DHR). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
InvestorPlaceInvest Like Bill Gates With These 3 AI Stocks to Buy
Bill Gates’ old company, Microsoft (NASDAQ:MSFT), would undoubtedly be on his list of AI stocks to buy. I suspect it’s on most AI investors’ must-own list. At the end of December, the Bill & Melinda Gates Foundation Trust had invested $42.3 billion in U.S.-listed stocks, according to the foundation’s 13F. Those assets were invested in 24 stocks, with Microsoft accounting for one-third of the portfolio’s assets. That means the average market value of the remaining 23 stocks was approximately $1.2
- Zacks
Danaher (DHR) Gains As Market Dips: What You Should Know
Danaher (DHR) reachead $248.46 at the closing of the latest trading day, reflecting a +0.27% change compared to its last close.
PR NewswireDanaher Schedules First Quarter 2024 Earnings Conference Call
Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the first quarter 2024 on Tuesday, April 23, 2024 beginning at 8:00 a.m. ET and lasting approximately one hour. During the call, the company will discuss its financial performance, as well as future expectations.
Insider Monkey11 Best Healthcare ETFs To Buy Now
In this article, we discuss 11 best healthcare ETFs to buy now. If you want to skip our discussion on the healthcare industry, head over to 5 Best Healthcare ETFs To Buy Now. In 2023, the healthcare sector faced challenges as investors adjusted portfolios in anticipation of higher interest rates. Although the sector lagged behind […]
Morningstar Rating
Rating
Fair Value
Economic Moat
People Also Watch
| Symbol | Last Price | Change | % Change |
|---|---|---|---|
| TMO Thermo Fisher Scientific Inc. | |||
| SYK Stryker Corporation | |||
| BDX Becton, Dickinson and Company | |||
| ZTS Zoetis Inc. | |||
| EL The Estée Lauder Companies Inc. |
Similar to DHR
| Symbol | Last Price | Change | % Change |
|---|---|---|---|
| TMO Thermo Fisher Scientific Inc. | |||
| IDXX IDEXX Laboratories, Inc. | |||
| A Agilent Technologies, Inc. | |||
| MTD Mettler-Toledo International Inc. | |||
| WAT Waters Corporation |
Analyst Price Targets (20)
Upgrades & Downgrades
| Maintains | Barclays: Equal-Weight to Equal-Weight | 4/10/2024 | |
| Maintains | Keybanc: Overweight to Overweight | 2/1/2024 | |
| Maintains | Citigroup: Buy to Buy | 1/31/2024 | |
| Maintains | RBC Capital: Outperform to Outperform | 1/31/2024 | |
| Maintains | Raymond James: Outperform to Outperform | 1/31/2024 | |
| Downgrade | Barclays: Overweight to Equal-Weight | 1/24/2024 |
Company Profile
2200 Pennsylvania Avenue, North West
Suite 800 West
Washington, DC 20037-1701
United States
202 828 0850
https://www.danaher.com
Sector(s): Healthcare
Industry: Diagnostics & Research
Full Time Employees: 61,000
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; microscopes; protein consumables; industrial filtration products; and genomic medicines, such as custom nucleic acid products, plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX and SCIEX brands. The Diagnostics segment offers chemistry, immunoassay, microbiology, and automation systems; and molecular, acute care, and pathology diagnostics products. This segment also provides clinical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is based in Washington, the District of Columbia.
